- Home
- Publications
- Publication Search
- Publication Details
Title
Oncolytic viruses for cancer immunotherapy
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-29
DOI
10.1186/s13045-020-00922-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors
- (2020) Caroline E. Porter et al. MOLECULAR THERAPY
- NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer
- (2020) Elaine Y.L. Leung et al. Molecular Therapy-Oncolytics
- Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
- (2020) Ciara M. Kelly et al. JAMA Oncology
- Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
- (2020) Victor Cervera-Carrascon et al. Molecular Therapy-Oncolytics
- A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
- (2019) Jean-Pascal Machiels et al. Journal for ImmunoTherapy of Cancer
- Second cancers and causes of death in patients with testicular cancer in Sweden
- (2019) Luyao Zhang et al. PLoS One
- Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
- (2019) Jason Chesney et al. BRITISH JOURNAL OF CANCER
- Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
- (2019) Julia Niemann et al. Nature Communications
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
- (2019) Hong Jiang et al. CLINICAL CANCER RESEARCH
- Artificially cloaked viral nanovaccine for cancer immunotherapy
- (2019) Manlio Fusciello et al. Nature Communications
- Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
- (2018) Junjie Wu et al. CANCER LETTERS
- Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
- (2018) Vincenzo Cerullo et al. CURRENT CANCER DRUG TARGETS
- Oncorine, the World First Oncolytic Virus Medicine and its Update in China
- (2018) Min Liang CURRENT CANCER DRUG TARGETS
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
- (2018) Frederick F. Lang et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy
- (2018) João Manuel Santos et al. MOLECULAR THERAPY
- Familial Associations in Testicular Cancer with Other Cancers
- (2018) Luyao Zhang et al. Scientific Reports
- Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
- (2018) Anna Wing et al. Cancer Immunology Research
- TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
- (2018) V. Cervera-Carrascon et al. OncoImmunology
- Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy
- (2018) Otto Hemminki et al. Molecular Therapy-Oncolytics
- Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
- (2018) Lillian Sun et al. Journal for ImmunoTherapy of Cancer
- Oncolytic Viruses for Multiple Myeloma Therapy
- (2018) Christine Calton et al. Cancers
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
- (2018) Antoni Ribas et al. CELL
- The advent of oncolytic virotherapy in oncology: The Rigvir® story
- (2018) Pēteris Alberts et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients
- (2018) Margarita Garcia et al. HUMAN GENE THERAPY
- Unleashing endogenous TNF-alpha as a cancer immunotherapeutic
- (2018) Steven F. Josephs et al. Journal of Translational Medicine
- CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
- (2018) Sadia Zafar et al. OncoImmunology
- Health and sustainability outcomes of vegetarian dietary patterns: a revisit of the EPIC-Oxford and the Adventist Health Study-2 cohorts
- (2018) Gina Segovia-Siapco et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis
- (2018) Nina Marí Gual Pimenta de Queiroz et al. MOLECULAR CANCER RESEARCH
- Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
- (2017) A Dispenzieri et al. LEUKEMIA
- Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy
- (2017) Sadia Zafar et al. OncoImmunology
- Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
- (2017) Riikka Havunen et al. Molecular Therapy-Oncolytics
- Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
- (2017) Sachin R. Jhawar et al. Frontiers in Oncology
- The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
- (2017) Assia L. Angelova et al. Frontiers in Oncology
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Spontaneous regression of tumour and the role of microbial infection – possibilities for cancer treatment
- (2016) Petra Kucerova et al. ANTI-CANCER DRUGS
- Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus
- (2016) Kristian Taipale et al. MOLECULAR THERAPY
- Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy
- (2016) Kristian Taipale et al. MOLECULAR THERAPY
- Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
- (2016) Mikko Siurala et al. MOLECULAR THERAPY
- Erratum: Oncolytic viruses: a new class of immunotherapy drugs
- (2016) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Role of Telomeres and Telomerase in Aging and Cancer
- (2016) J. W. Shay Cancer Discovery
- Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model
- (2016) Eonju Oh et al. Oncotarget
- Role of IL-2 in cancer immunotherapy
- (2016) Tao Jiang et al. OncoImmunology
- Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
- (2016) Tuuli Ranki et al. Journal for ImmunoTherapy of Cancer
- Case–Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors
- (2015) Anna Kanerva et al. MOLECULAR THERAPY
- Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues
- (2015) Anniina Koski et al. MOLECULAR THERAPY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Immunological data from cancer patients treated with Ad5/3 E2F Δ24 GMCSF suggests utility for tumor immunotherapy
- (2015) Otto Hemminki et al. Oncotarget
- A century of oncolysis evolves into oncolytic immunotherapy
- (2015) O. Hemminki et al. OncoImmunology
- Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
- (2015) Ilkka Liikanen et al. OncoImmunology
- Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors
- (2015) Siri Tähtinen et al. PLoS One
- A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
- (2014) D. W. Sborov et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
- (2014) A. Rodriguez-Garcia et al. CLINICAL CANCER RESEARCH
- Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response, prominent infiltration of CD8+lymphocytes and Th1 type polarization
- (2014) Tuuli Ranki et al. OncoImmunology
- Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus
- (2013) A. Kanerva et al. CLINICAL CANCER RESEARCH
- In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders
- (2013) O. Hemminki et al. INTERNATIONAL JOURNAL OF CANCER
- Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans
- (2013) Simona Bramante et al. INTERNATIONAL JOURNAL OF CANCER
- Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients
- (2013) Ilkka Liikanen et al. MOLECULAR THERAPY
- Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism
- (2013) Anniina Koski et al. PLoS One
- Penton-Dodecahedral Particles Trigger Opening of Intercellular Junctions and Facilitate Viral Spread during Adenovirus Serotype 3 Infection of Epithelial Cells
- (2013) Zhuo-Zhuang Lu et al. PLoS Pathogens
- Harnessing the Power of the Immune System to Target Cancer
- (2012) Gregory Lizée et al. Annual Review of Medicine
- CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer
- (2012) Can Xu et al. CANCER LETTERS
- An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance
- (2012) Vincenzo Cerullo et al. MOLECULAR THERAPY
- Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer
- (2012) Otto Hemminki et al. MOLECULAR THERAPY
- Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
- (2012) R. A. Adair et al. Science Translational Medicine
- Adenovirus receptors: implications for targeting of viral vectors
- (2012) Niklas Arnberg TRENDS IN PHARMACOLOGICAL SCIENCES
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
- (2011) J D Dias et al. GENE THERAPY
- Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors
- (2011) Sari Pesonen et al. INTERNATIONAL JOURNAL OF CANCER
- Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial Junctions
- (2011) H. Wang et al. JOURNAL OF VIROLOGY
- Sodium Iodide Symporter SPECT Imaging of a Patient Treated With Oncolytic Adenovirus Ad5/3-Δ24-hNIS
- (2011) Maria Rajecki et al. MOLECULAR THERAPY
- Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus
- (2011) Ilkka Liikanen et al. MOLECULAR THERAPY
- Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer
- (2011) Anniina Koski et al. MOLECULAR THERAPY
- Cytokines in Cancer Immunotherapy
- (2011) Sylvia Lee et al. Cancers
- A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers
- (2010) Jianhua Chang et al. CANCER BIOLOGY & THERAPY
- Oncolytic adenovirus based on serotype 3
- (2010) O Hemminki et al. CANCER GENE THERAPY
- Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
- (2010) Vincenzo Cerullo et al. CANCER RESEARCH
- Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
- (2010) P. Nokisalmi et al. CLINICAL CANCER RESEARCH
- Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic and antitumor efficacy
- (2010) T Cherry et al. GENE THERAPY
- Hematopoietic Stem Cell TransplantationA Global Perspective
- (2010) Alois Gratwohl JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
- (2010) Anniina Koski et al. MOLECULAR THERAPY
- Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
- (2010) Hongjie Wang et al. NATURE MEDICINE
- Delivering nanomedicine to solid tumors
- (2010) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Increasing the Efficacy of Oncolytic Adenovirus Vectors
- (2010) Karoly Toth et al. Viruses-Basel
- Cancer Prevention: From 1727 to Milestones of the Past 100 Years
- (2009) Scott M. Lippman et al. CANCER RESEARCH
- Replacement of Adenovirus Type 5 Fiber Shaft Heparan Sulfate Proteoglycan-Binding Domain with RGD for Improved Tumor Infectivity and Targeting
- (2009) Neus Bayo-Puxan et al. HUMAN GENE THERAPY
- Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation
- (2009) Maria Rajecki et al. INTERNATIONAL JOURNAL OF CANCER
- A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers
- (2008) Xinghua Wang et al. MOLECULAR CANCER THERAPEUTICS
- Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
- (2008) Irene Kuhn et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now